Feasibility and predictive factors on the completion of docetaxel plus S‐1 adjuvant chemotherapy in pathological stage III gastric cancer by Masayoshi Terayama, Manabu Ohashi, Kensei Yamaguchi, Daisuke Takahari, Rie Makuuchi, Masaru Hayami, Satoshi Ida, Koshi Kumagai, Takeshi Sano, Souya Nunobe

Get full text

Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings by Koshiro Fukuda, Hiroki Osumi, Keitaro Shimozaki, Keisho Chin, Mariko Ogura, Shota Fukuoka, Shohei Udagawa, Koichiro Yoshino, Mikako Tamba, Takeru Wakatsuki, Eiji Shinozaki, Kensei Yamaguchi, Akira Ooki

Get full text

Investigating the role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011 and 2023 by Keitaro Shimozaki, Akira Ooki, Koichiro Yoshino, Mikako Tamba, Shohei Udagawa, Hiroki Osumi, Shota Fukuoka, Izuma Nakayama, Takeru Wakatsuki, Mariko Ogura, Daisuke Takahari, Eiji Shinozaki, Keisho Chin, Kensei Yamaguchi

Get full text

Real-world safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma by Mikako Tamba, Hiroki Osumi, Mariko Ogura, Shota Fukuoka, Akihiko Okamura, Jun Kanamori, Yu Imamura, Koichiro Yoshino, Shohei Udagawa, Takeru Wakatsuki, Eiji Shinozaki, Masayuki Watanabe, Kensei Yamaguchi, Keisho Chin, Akira Ooki

Get full text

Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomark... by Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, Kensei Yamaguchi, Tomohiro Nishina, Elena Elez, Javier Rodriguez, Ian Chau, Maria Di Bartolomeo, Hisato Kawakami, Fumitaka Suto, Makito Koga, Koichiro Inaki, Yusuke Kuwahara, Issey Takehara, Daniel Barrios, Kojiro Kobayashi, Axel Grothey, Takayuki Yoshino

Get full text